Novo Nordisk's Rybelsus hasn't lived up to expectations, say analysts
The Danish drugmaker’s diabetes pill hasn’t reached the success that was predicted three years ago, to the disappointment of analysts.
by marketwire, translated by daniel pedersen
Novo Nordisk’s Rybelsus, a diabetes pill, is far from becoming the huge sales success it was heralded as prior to launching -- a realization that is now disappointing analysts, reports Danish financial media Finans.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.